Homepage
Author:
IGC Pharma, Inc.
Posted Date:
April 8, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
IGC Pharma, Inc.
April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease
IGC Pharma, Inc.
April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
IGC Pharma, Inc.
March 30, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
IGC Pharma, Inc.
March 19, 2026
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026
IGC Pharma, Inc.
March 18, 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research
IGC Pharma, Inc.
February 26, 2026
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
IGC Pharma, Inc.
February 24, 2026
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
IGC Pharma, Inc.
February 23, 2026
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
IGC Pharma, Inc.
February 18, 2026
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
IGC Pharma, Inc.
February 17, 2026
1
2
Next
